Premium
Ocular irritation from high‐dose methotrexate therapy: Pharmacokinetics of drug in the tear film
Author(s) -
Doroshow James H.,
Locker Gershon Y.,
Gaasterland Douglas E.,
Hubbard Susan P.,
Young Robert C.,
Myers Charles E.
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19811115)48:10<2158::aid-cncr2820481007>3.0.co;2-i
Subject(s) - methotrexate , medicine , irritation , pharmacokinetics , chemotherapy , tears , artificial tears , drug , anesthesia , surgery , dermatology , pharmacology , immunology
Four of 13 patients receiving intermittent high‐dose methotrexate therapy experienced recurrent symptoms of ocular irritation (burning, pruritus, “dry eyes”) two to seven days after chemotherapy. Ophthalmic examination was unremarkable in symptomatic individuals except for decreased reflex production of tears in some patients. Pharmacokinetic studies of a group of these patients revealed concentrations of methotrexate in tears equivalent to those in plasma at 24 and 48 hours after treatment; these concentrations reached 1 × 10 −5 M during the infusion of methotrexate. The occurrence of acidic lacrimal secretions, p H 6.5 in one symptomatic patient, may have contributed to decreased solubility of methotrexate in the fluid of the conjunctival sac.